Disclosed are an inflammation-targeted neutrophil granulocyte drug delivery system and use thereof, wherein the drug delivery system includes neutrophil granulocytes and a therapeutic substance or a detectable substance loaded into the neutrophil granulocytes or onto the surface of the neutrophil granulocytes in a direct or indirect way. By using the neutrophil granulocytes as a carrier of a drug, the drug is actively targeted to an inflammatory site, thereby increasing the drug concentration at the inflammatory site. Under the stimulation of cytokines, the neutrophil granulocytes arriving at the inflammatory site are abnormally activated, disintegrate rapidly, and die in the way of “Neutrophil extracellular traps (NETs)”. This helps to rapidly release the loaded drug to the targeted site, so as to improve the therapeutic effect and reduce the toxic and side effects.

Kits, compositions and methods for enriching myeloid-derived suppressor cells (MDSCs) are provided. In one embodiment, the kit comprises (a) one or more antibodies or fragments thereof that bind one or more non-MDSC target cells; and (b) a plurality of particles, wherein the plurality of particles are linked or linkable to at least one of the one or more antibodies.

The disclosure provides methods for the long-term expansion of granulocyte-macrophage progenitors, the granulocyte-macrophage progenitors generated therefrom, and uses of the granulocyte-macrophage progenitors thereof.

The present invention relates to an in vitro culture of haematopoietic cells, wherein said haematopoietic cells differentiate to form granulocytes characterised by the ability to kill cancer cells. The invention also relates to said granulocytes, methods for identifying said haematopoietic cells and granulocytes, compositions and kits comprising the same, as well as uses of the same for treating cancer.

A method of treating a disease or disorder that can benefit from increasing an M2/M1 macrophage ratio in a subject in need thereof is provided. The method comprising: (a) culturing basophils in the presence of IL33 and/or GM-SCF; and (b) administering to the subject a therapeutically effective amount of the basophils following the culturing, thereby treating the disease or disorder that can benefit from increasing an M2/M1 macrophage ratio in the subject.

In one aspect, a method of treating a subject having or at risk of having graft-versus-host disease (GvHD) generally includes administering to the subject a plurality of myeloid-derived suppressor cells (MDSCs) effective to ameliorate at least one symptom or clinical sign of graft-versus-host disease compared to a suitable control subject. In another aspect, a method of treating a tumor in a subject generally includes administering to the subject an anti-tumor therapy and co-administering to the subject an inflammasome inciting agent in an amount effective to increase inflammasome activation of MDSCs sufficiently to reduce suppressor function of the MDSCs.

The present invention relates to stem-cell derived hematopoietic cells, in particular, myeloid cells, preferably, macrophages, their generation and use. In particular, the invention relates to a method of producing hematopoietic, preferably, myeloid cells, comprising cultivating embryoid bodies, which are, e.g., derivable from pluripotent stem cells such as induced pluripotent stem cells (iPSC), in suspension culture, to produce myeloid cell forming complexes, which are further cultivated in suspension culture to produce myeloid cells such as macrophages. This allows for a scalable and continuous production, e.g., in industry-compatible stirred tank bioreactors. Macrophages, e.g., macrophages produced with this method that have unique characteristics, can be used in pharmaceutical compositions for treatment of patients, e.g., for treatment of infection such as bacterial infection. The invention further provides application systems suitable for spraying, comprising myeloid cells such as macrophages, which can have a reduced size, for use in treatment of patients for treatment of infection, e.g., bacterial infection or wound healing.

A system for cell bioprocessing and cell therapy manufacturing can include a series of microfluidic modules to enable continuous-flow end-to-end cell bioprocessing. Each module can implement a different technology, and the modules can be coupled to one another to perform various unit operations in the cell bioprocessing or cell-therapy manufacturing chain to enable direct processing of a blood or blood product sample. The system can automatically and continuously process the sample into genetically-modified lymphocytes or T cells for cellular therapy. The technologies implemented by each module in the system can include any combination of microfluidic acoustophoresis, microfluidic acoustophoretic media exchange or cell washing, and continuous-flow microfluidic electrotransfection. Modules implementing these microfluidic technologies can be interconnected with plastic tubing or with a custom manifold.

The present invention provides a method for preparing a cell culture medium comprising a mixture of blood products from two or more donors, comprising the steps of: a) providing at least a first blood product from a first donor; b) measuring the concentration of at least one quality factor in the first blood product; c) comparing the measured concentration of a quality factor to a concentration range predefined for the quality factor; d) selecting the first blood product for the cell culture medium if the concentration measured for the quality factor is in the predefined range and optionally converting the first selected blood product into a first processed blood product or else unselecting the first blood product.

Disclosed is a method of characterising and/or separating neutrophils, the method comprises characterising and/or separating the neutrophils into a first population comprising proliferative neutrophils and a second population comprising mature neutrophils, according to the expression of CD101 on the neutrophils. Also disclosed are compositions comprising proliferative neutrophils that are CD10.sup.−CD101.sup.−, and methods of treatment, diagnostic or prognostic using neutrophils thereof, as well as kits for characterising and/or separating proliferative neutrophils based on the expression of CD101 or CD10. In a preferred embodiment, the population of neutrophils may be characterised as proliferative neutrophils if CD10.sup.−CD101.sup.−, as immature neutrophils if CD10.sup.−CD101.sup.+ and as mature neutrophils if CD10.sup.+CD101.sup.+.